A Ph1 Randomized Double-Blind Controlled Dose-Range Safety Tolerability & Immunogenicity Study of 2 Doses of Intranasal rH5 Flu Vaccine With & Without Nanoemulsion Adjuvant Followed by 1 Boost of Intramuscular H5N1 Vaccine in Healthy Adults
Latest Information Update: 26 Aug 2024
At a glance
- Drugs BW-1014 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms IN-NE-rH5
- Sponsors BlueWillow Biologics
Most Recent Events
- 22 Aug 2024 Status changed from active, no longer recruiting to completed.
- 21 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 08 Jul 2022 Status changed from not yet recruiting to recruiting.